Omeros (NASDAQ:OMER) Downgraded by ValuEngine to “Hold”

Omeros (NASDAQ:OMER) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, June 26th, ValuEngine reports.

Other equities research analysts have also recently issued reports about the stock. BidaskClub cut shares of Xencor from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 11th. Wedbush set a $20.00 price objective on shares of Plymouth Industrial Reit and gave the company a “buy” rating in a report on Monday, May 20th. Cantor Fitzgerald reissued a “buy” rating and issued a $71.00 price objective on shares of ExlService in a report on Monday, May 6th. Zacks Investment Research raised shares of Garrett Motion from a “sell” rating to a “hold” rating in a research note on Friday, May 10th. Finally, HC Wainwright set a $55.00 target price on shares of Acer Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.80.

Shares of OMER stock traded up $0.04 during trading hours on Wednesday, hitting $15.49. The company’s stock had a trading volume of 237,955 shares, compared to its average volume of 524,451. The stock has a 50 day simple moving average of $16.23. Omeros has a 12-month low of $10.30 and a 12-month high of $27.00. The stock has a market cap of $756.51 million, a PE ratio of -6.98 and a beta of 3.04.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The business had revenue of $21.80 million for the quarter, compared to the consensus estimate of $23.18 million. The business’s revenue for the quarter was up 1271.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.62) EPS. Equities research analysts forecast that Omeros will post -1.68 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of OMER. Rhumbline Advisers lifted its holdings in shares of Omeros by 73.3% in the fourth quarter. Rhumbline Advisers now owns 72,243 shares of the biopharmaceutical company’s stock valued at $805,000 after purchasing an additional 30,547 shares in the last quarter. Miramar Capital LLC bought a new stake in Omeros during the fourth quarter worth about $192,000. Quad Cities Investment Group LLC raised its holdings in Omeros by 28.2% during the first quarter. Quad Cities Investment Group LLC now owns 13,650 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 3,000 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in Omeros by 49.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock worth $21,303,000 after acquiring an additional 632,840 shares in the last quarter. Finally, Capital Impact Advisors LLC raised its holdings in Omeros by 42.6% during the fourth quarter. Capital Impact Advisors LLC now owns 136,570 shares of the biopharmaceutical company’s stock worth $1,581,000 after acquiring an additional 40,815 shares in the last quarter. Institutional investors own 52.12% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Hedge Funds Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.